NCT00925782 - PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

July 31, 2011

Conditions

Multiple Myeloma

Interventions

DRUG

Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection

Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.

DRUG

Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)

Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.

Trial Locations (1)

66160

University of Kansas Medical Center/University of Kansas Cancer Center and Medical Pavillion, Kansas City